View in EDS HTML Full Text PDF Full Text

How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.

Saved in:
Bibliographic Details
Title: How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.
Authors: Blacher, RachelJ. (AUTHOR), Muiruri, Peter (AUTHOR), Njobvu, Lungowe (AUTHOR), Mutsotso, Winnie (AUTHOR), Potter, Dara (AUTHOR), Ong'ech, John (AUTHOR), Mwai, Paul (AUTHOR), Degroot, Alain (AUTHOR), Zulu, Isaac (AUTHOR), Bolu, Omotayo (AUTHOR), Stringer, Jeffrey (AUTHOR), Kiarie, James (AUTHOR), Weidle, PaulJ. (AUTHOR)
Source: AIDS Care. Nov2010, Vol. 22 Issue 11, p1323-1331. 9p. 3 Charts.
Subjects: Confidence intervals, Drugs, Epidemiology, HIV infections, Medical appointments, Patient compliance, Self-evaluation, Women, Women's health, Data analysis, Viral load, Multiple regression analysis, Highly active antiretroviral therapy, Drug therapy
Geographic Terms: Africa
Abstract: Collecting self-reported data on adherence to highly active antiretroviral therapy (HAART) can be complicated by patients' reluctance to report poor adherence. The timeliness with which patients attend visits might be a useful alternative to estimate medication adherence. Among Kenyan and Zambian women receiving twice daily HAART, we examined the relationship between self-reported pill taking and timeliness attending scheduled visits. We analyzed data from 566 Kenyan and Zambian women enrolled in a prospective 48-week HAART-response study. At each scheduled clinic visit, women reported doses missed over the preceding week. Self-reported adherence was calculated by summing the total number of doses reported taken and dividing by the total number of doses asked about at the visit attended. A participant's adherence to scheduled study visits was defined as 'on time' if she arrived early or within three days, 'moderately late' if she was four-seven days late, and 'extremely late/missed' if she was more than eight days late or missed the visit altogether. Self-reported adherence was <95% for 29 (10%) of 288 women who were late for at least one study visit vs. 3 (1%) of 278 who were never late for a study visit (odds ratios [OR] 10.3; 95% confidence intervals [95% CI] 2.9, 42.8). Fifty-one (18%) of 285 women who were ever late for a study visit experienced virologic failure vs. 32 (12%) of 278 women who were never late for a study visit (OR 1.7; 95% CI 1.01, 2.8). A multivariate logistic regression model controlling for self-reported adherence found that being extremely late for a visit was associated with virologic failure (OR 2.0; 95% CI 1.2, 3.4). Timeliness to scheduled visits was associated with self-reported adherence to HAART and with risk for virologic failure. Timeliness to scheduled clinic visits can be used as an objective proxy for self-reported adherence and ultimately for risk of virologic failure. [ABSTRACT FROM AUTHOR]
Copyright of AIDS Care is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 54330160
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Blacher%2C+RachelJ%2E%22&quot;&gt;Blacher, RachelJ.&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Muiruri%2C+Peter%22&quot;&gt;Muiruri, Peter&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Njobvu%2C+Lungowe%22&quot;&gt;Njobvu, Lungowe&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mutsotso%2C+Winnie%22&quot;&gt;Mutsotso, Winnie&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Potter%2C+Dara%22&quot;&gt;Potter, Dara&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ong&#39;ech%2C+John%22&quot;&gt;Ong&#39;ech, John&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mwai%2C+Paul%22&quot;&gt;Mwai, Paul&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Degroot%2C+Alain%22&quot;&gt;Degroot, Alain&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zulu%2C+Isaac%22&quot;&gt;Zulu, Isaac&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bolu%2C+Omotayo%22&quot;&gt;Bolu, Omotayo&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Stringer%2C+Jeffrey%22&quot;&gt;Stringer, Jeffrey&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kiarie%2C+James%22&quot;&gt;Kiarie, James&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Weidle%2C+PaulJ%2E%22&quot;&gt;Weidle, PaulJ.&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22AIDS+Care%22&quot;&gt;AIDS Care&lt;/searchLink&gt;. Nov2010, Vol. 22 Issue 11, p1323-1331. 9p. 3 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Confidence+intervals%22&quot;&gt;Confidence intervals&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Drugs%22&quot;&gt;Drugs&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Epidemiology%22&quot;&gt;Epidemiology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HIV+infections%22&quot;&gt;HIV infections&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medical+appointments%22&quot;&gt;Medical appointments&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Patient+compliance%22&quot;&gt;Patient compliance&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Self-evaluation%22&quot;&gt;Self-evaluation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Women%22&quot;&gt;Women&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Women&#39;s+health%22&quot;&gt;Women&#39;s health&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Data+analysis%22&quot;&gt;Data analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Viral+load%22&quot;&gt;Viral load&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Multiple+regression+analysis%22&quot;&gt;Multiple regression analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Highly+active+antiretroviral+therapy%22&quot;&gt;Highly active antiretroviral therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Drug+therapy%22&quot;&gt;Drug therapy&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Africa%22&quot;&gt;Africa&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Collecting self-reported data on adherence to highly active antiretroviral therapy (HAART) can be complicated by patients&#39; reluctance to report poor adherence. The timeliness with which patients attend visits might be a useful alternative to estimate medication adherence. Among Kenyan and Zambian women receiving twice daily HAART, we examined the relationship between self-reported pill taking and timeliness attending scheduled visits. We analyzed data from 566 Kenyan and Zambian women enrolled in a prospective 48-week HAART-response study. At each scheduled clinic visit, women reported doses missed over the preceding week. Self-reported adherence was calculated by summing the total number of doses reported taken and dividing by the total number of doses asked about at the visit attended. A participant&#39;s adherence to scheduled study visits was defined as &#39;on time&#39; if she arrived early or within three days, &#39;moderately late&#39; if she was four-seven days late, and &#39;extremely late/missed&#39; if she was more than eight days late or missed the visit altogether. Self-reported adherence was &lt;95% for 29 (10%) of 288 women who were late for at least one study visit vs. 3 (1%) of 278 who were never late for a study visit (odds ratios [OR] 10.3; 95% confidence intervals [95% CI] 2.9, 42.8). Fifty-one (18%) of 285 women who were ever late for a study visit experienced virologic failure vs. 32 (12%) of 278 women who were never late for a study visit (OR 1.7; 95% CI 1.01, 2.8). A multivariate logistic regression model controlling for self-reported adherence found that being extremely late for a visit was associated with virologic failure (OR 2.0; 95% CI 1.2, 3.4). Timeliness to scheduled visits was associated with self-reported adherence to HAART and with risk for virologic failure. Timeliness to scheduled clinic visits can be used as an objective proxy for self-reported adherence and ultimately for risk of virologic failure. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of AIDS Care is the property of Taylor &amp; Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=54330160
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/09540121003692235
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 1323
    Subjects:
      – SubjectFull: Confidence intervals
        Type: general
      – SubjectFull: Drugs
        Type: general
      – SubjectFull: Epidemiology
        Type: general
      – SubjectFull: HIV infections
        Type: general
      – SubjectFull: Medical appointments
        Type: general
      – SubjectFull: Patient compliance
        Type: general
      – SubjectFull: Self-evaluation
        Type: general
      – SubjectFull: Women
        Type: general
      – SubjectFull: Women's health
        Type: general
      – SubjectFull: Data analysis
        Type: general
      – SubjectFull: Viral load
        Type: general
      – SubjectFull: Multiple regression analysis
        Type: general
      – SubjectFull: Highly active antiretroviral therapy
        Type: general
      – SubjectFull: Drug therapy
        Type: general
      – SubjectFull: Africa
        Type: general
    Titles:
      – TitleFull: How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Blacher, RachelJ.
      – PersonEntity:
          Name:
            NameFull: Muiruri, Peter
      – PersonEntity:
          Name:
            NameFull: Njobvu, Lungowe
      – PersonEntity:
          Name:
            NameFull: Mutsotso, Winnie
      – PersonEntity:
          Name:
            NameFull: Potter, Dara
      – PersonEntity:
          Name:
            NameFull: Ong'ech, John
      – PersonEntity:
          Name:
            NameFull: Mwai, Paul
      – PersonEntity:
          Name:
            NameFull: Degroot, Alain
      – PersonEntity:
          Name:
            NameFull: Zulu, Isaac
      – PersonEntity:
          Name:
            NameFull: Bolu, Omotayo
      – PersonEntity:
          Name:
            NameFull: Stringer, Jeffrey
      – PersonEntity:
          Name:
            NameFull: Kiarie, James
      – PersonEntity:
          Name:
            NameFull: Weidle, PaulJ.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2010
              Type: published
              Y: 2010
          Identifiers:
            – Type: issn-print
              Value: 09540121
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: AIDS Care
              Type: main
ResultId 1